Mucosal Lymphocyte Homing in the Head and Neck
Mucosal Lymphocyte Homing in the Head and Neck
批准号:
6864865
负责人:
David W Pascual
金额:
$31.84万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2009-03-31
关键词:
B lymphocytecell adhesion moleculescell migrationcell population studycholera toxindrug administration routesenzyme linked immunosorbent assayheadimmunizationlaboratory mouseleukocyte adhesion moleculesmonoclonal antibodymucosal immunityneckreceptor expressionrespiratory systemsalivary glandsselectins
中文摘要
描述:我们以前的研究表明,鼻部相关淋巴组织(NALT)和各种头颈部淋巴结(LN)表达独特的寻址模式。这些淋巴组织中的高内皮微静脉(HEV)与广泛存在MAdCAM-1的Peyer‘s Patch(PP)HEV不同。相反,周围结节寻址蛋白(PNAD)主导着这些组织,特别是考虑到其他研究人员过去的研究表明,粘膜B细胞向小肠固有层(ILP)的迁移依赖于MAdCAM-1和α4beta7的相互作用,在较小程度上依赖于L-选择素,这表明粘膜淋巴细胞归巢的另一种模式。事实上,效应器B细胞免疫与α4β7/高表型分离。在本申请中,我们提出至少存在另外两个不是α4β7/高的粘膜B细胞亚群。一个B细胞亚群被鉴定为L-选择素/低α4β7/低,另一个被鉴定为αEβ7+。小鼠鼻内注射(I.N.)霍乱毒素(CT)免疫后,鼻腔(NP)、生殖道(RT)和颌下腺(SMG)主要显示L-选择素/低α4β7/低效B细胞。对I.N.的评价CT免疫的L-选择素缺陷小鼠在NP中没有粘膜效应B细胞,但ILP反应维持在αEbeta7+,而不是Alpha4beta7/High。总之,这些数据表明L-选择素对于抗原(Ag)特异性效应B细胞在非肠道粘膜组织中的迁移是重要的。因此,这一建议将表征I.N.后L选择的低α4β7/低和αEβ7+B细胞的功能属性。或口服CT免疫。具体目标1的研究将确定L-选择素和α4β7在I.N后诱导性和效应性B细胞免疫发展中的相对重要性。或口服免疫。针对特定目标2的研究将确定所描述的新型L-选择素/低α4β7/低或αβ7+B细胞是否可以定位于非肠道和肠粘膜效应组织。针对特定目标3的研究将确定哪个B细胞亚群,L-选择素/低α4β7/低或αEβ7+,对I.N具有保护作用。与CT一起挑战。从这项工作中,我们将了解如何使用免疫途径有效地将疫苗靶向非肠道粘膜部位。
英文摘要
DESCRIPTION: Work from our previous studies has shown that the nasal-associated lymphoid tissue (NALT) and the various head and neck lymph nodes (LN) express unique addressin patterns. The high endothelial venules (HEV) from these lymphoid tissues do not resemble Peyer's patch (PP) HEV with the extensive presence of MAdCAM-1. Instead, the peripheral node addressin (PNAd) dominates these tissues, suggesting an alternative mode of mucosal lymphocyte homing especially in light of past studies by other investigators showing that mucosal B cell migration to small intestinal lamina propria (iLP) is dependent upon MAdCAM- 1-alpha4beta7 interactions, and to a lesser degree, upon L-selectin. In fact, effector B cell immunity segregated with the alpha4beta7/high phenotype. Herein this application, we propose that at least two other mucosal B cell subsets exist that are not alpha4beta7/high.One B cell subset is identified as L-selectin/low alpha4beta7/low, the other, alphaEbeta7+. In mice intranasally (i.n.) immunized with cholera toxin (CT), we show primarily L-selectin/low alpha4beta7/low effector B cells in the nasal passages (NP), reproductive tract (RT), and submaxillary gland (SMG). Evaluation of i.n. CT-immunized L-selectin-deficient mice show an absence of mucosal effector B ceils in the NP, but iLP responses were maintained as alphaEbeta7+, not alpha4beta7/high. Collectively, these data suggest that L-selectin is important for the migration of antigen (Ag)-specific effector B cells in nonintestinal mucosal tissues. Thus, this proposal will characterize the functional attributes of L-selectinlow alpha4beta7/low and alphaEbeta7+B cells subsequent to i.n. or oral immunization with CT. Studies in Specific Aim 1 will determine the relative importance of L-selectin and alpha4beta7 to the development of both inductive and effector B cell immunity subsequent to i.n. or oral immunization. Studies in Specific Aim 2 will determine determine if the described novel L-selectin/low alpha4beta7/low or alphaEbeta7+ B cells can home to nonintestinal as well as intestinal mucosal effector tissues. Studies in Specific Aim 3 will determine which B cell subset, L-selectin/low alpha4beta7/low or alphaEbeta7+, is protective against i.n. challenge with CT. From this work, we will learn how routes of immunizations can be used to effectively target vaccines to nonintestinal mucosal sites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Snodgrassella alvi as an attenuated live vaccine against Neisseria gonorrhoeae
-
批准号:10263891
-
项目类别:
-
资助金额:$24.19万
-
财政年份:2020
-
负责人:David W Pascual
-
依托单位:
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
-
批准号:9751725
-
项目类别:
-
资助金额:$37.71万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Regulatory Cell Therapy for Sjogrens Syndrome
-
批准号:10898203
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
-
批准号:10213597
-
项目类别:
-
资助金额:$37.67万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
-
批准号:9977090
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2017
-
负责人:David W Pascual
-
依托单位:
Sony Cell Sorter SH800 System
-
批准号:9075724
-
项目类别:
-
资助金额:$29.56万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
Mucosal Vaccines for Brucellosis
-
批准号:9079710
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
Fimbriae Countermeasures for Type 1 Diabetes
-
批准号:9242580
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2016
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8651868
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8827663
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8076096
-
项目类别:
-
资助金额:$51.55万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
MT VET COBRE II CORE C: ANIMAL MODELS
-
批准号:8360160
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8460570
-
项目类别:
-
资助金额:$44.4万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8262375
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Subunit Vaccines for Brucella Pathogens"
-
批准号:8580995
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2011
-
负责人:David W Pascual
-
依托单位:
"Mechanisms of IL-35 Protection Against Arthritis"
-
批准号:8124930
-
项目类别:
-
资助金额:$16.0万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
MT VET COBRE II CORE C: ANIMAL MODELS
-
批准号:8168414
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
"Mechanisms of IL-35 Protection Against Arthritis"
-
批准号:7917759
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2010
-
负责人:David W Pascual
-
依托单位:
Mucosal Therapy for Autoimmunity
-
批准号:8220951
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2009
-
负责人:David W Pascual
-
依托单位:
Mucosal Therapy for Autoimmunity
-
批准号:7675115
-
项目类别:
-
资助金额:$17.81万
-
财政年份:2009
-
负责人:David W Pascual
-
依托单位:
海外基金